Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC8 | Q9BY41 | 20/20 | 1.00 |
| ▸ | HDAC1 | Q13547 | 19/20 | 1.00 |
| ▸ | HDAC3 | O15379 | 18/20 | 1.00 |
| ▸ | HDAC4 | P56524 | 18/20 | 1.00 |
| ▸ | HDAC7 | Q8WUI4 | 18/20 | 1.00 |
| ▸ | HDAC2 | Q92769 | 18/20 | 1.00 |
| ▸ | HDAC10 | Q969S8 | 18/20 | 1.00 |
| ▸ | HDAC11 | Q96DB2 | 18/20 | 1.00 |
| ▸ | HDAC6 | Q9UBN7 | 18/20 | 1.00 |
| ▸ | HDAC9 | Q9UKV0 | 18/20 | 1.00 |
| ▸ | HDAC5 | Q9UQL6 | 18/20 | 1.00 |
| ▸ | BRD4 | O60885 | 1/20 | 0.85 |
| ▸ | ESR1 | P03372 | 1/20 | 0.85 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.85 |
| ▸ | PDE4A | P27815 | 1/20 | 0.85 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.85 |
| ▸ | HTR6 | P50406 | 1/20 | 0.85 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.85 |
| ▸ | ASPH | Q12797 | 1/20 | 0.85 |
| ▸ | MEN1 | O00255 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1403252 | 1.00 | HDAC8 (1.00) | HDAC8HDAC1HDAC3HDAC4HDAC7 | |
| SCHEMBL1403555 | 0.93 | HDAC1 (1.00) | HDAC8HDAC1HDAC3HDAC4HDAC7 | |
| SCHEMBL1403553 | 0.93 | HDAC1 (1.00) | HDAC8HDAC1HDAC3HDAC4HDAC7 | |
| Belinostat SCHEMBL29712104 | 0.92 | HDAC1 (1.00) | HDAC8HDAC1HDAC3HDAC4HDAC7 | |
| Belinostat SCHEMBL29379950 | 0.92 | HDAC1 (1.00) | HDAC8HDAC1HDAC3HDAC4HDAC7 | |
| Belinostat SCHEMBL375906 | 0.92 | HDAC1 (1.00) | HDAC8HDAC1HDAC3HDAC4HDAC7 | |
| Belinostat SCHEMBL375656 | 0.92 | HDAC1 (1.00) | HDAC8HDAC1HDAC3HDAC4HDAC7 | |
| SCHEMBL8770039 | 0.91 | HDAC8 (0.84) | HDAC8HDAC1HDAC3HDAC4HDAC7 | |
| SCHEMBL8770042 | 0.91 | HDAC8 (0.84) | HDAC8HDAC1HDAC3HDAC4HDAC7 | |
| SCHEMBL1413382 | 0.89 | HDAC1 (1.00) | HDAC8HDAC1HDAC3HDAC4HDAC7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115925708-A | Belinostat theophylline eutectic crystal and preparation method and application thereof | 天津大学 | 2023-04-07 | — | — | CN | disclosed |
| CN-115838343-A | belinostat-L-proline zwitter-ion eutectic and preparation method and application thereof | 天津大学 | 2023-03-24 | — | — | CN | disclosed |
| US-9957227-B2 | Pharmaceutical formulations of HDAC inhibitors | TOPOTARGET UK LIMITED (GB) | 2018-05-01 | — | — | US | disclosed |
| US-20180072661-A1 | PHARMACEUTICAL FORMULATIONS OF HDAC INHIBITORS | TOPOTARGET UK LIMITED (GB) | 2018-03-15 | — | — | US | disclosed |
| EP-2494969-B1 | Pharmaceutical formulations of HDAC inhibitors | TOPOTARGET UK LTD (GB) | 2015-03-25 | — | — | EP | disclosed |
| US-20150031770-A1 | Pharmaceutical Formulations of HDAC Inhibitors | TOPOTARGET UK LIMITED (GB) | 2015-01-29 | — | — | US | disclosed |
| US-8835501-B2 | Pharmaceutical formulations of HDAC inhibitors | TOPOTARGET UK LIMITED (GB) | 2014-09-16 | — | — | US | disclosed |
| US-8835501-B2 | Pharmaceutical formulations of HDAC inhibitors | TOPOTARGET UK LIMITED (GB) | 2014-09-16 | — | — | US | disclosed |
| EP-2494969-A1 | Pharmaceutical formulations of HDAC inhibitors | TopoTarget UK Limited (GB) | 2012-09-05 | — | — | EP | disclosed |
| US-20110105572-A1 | CARBAMIC ACID COMPOUNDS COMPRISING AN AMIDE LINKAGE AS HDAC INHIBITORS | TOPOTARGET UK LIMITED (GB) | 2011-05-05 | — | — | US | disclosed |
| WO-2006120456-A1 | PHARMACEUTICAL FORMULATIONS OF HDAC INHIBITORS | TOPOTARGET UK LIMITED (GB) | 2006-11-16 | — | — | WO | disclosed |
| US-20050107445-A1 | Carbamic acid compounds comprising a sulfonamide linkage as HDAC inhibitors | PROLIFIX LIMITED (GB) | 2005-05-19 | — | — | US | disclosed |
| US-6888027-B2 | Carbamic acid compounds comprising a sulfonamide linkage as HDAC inhibitors | TOPOTARGET UK LIMITED (GB) | 2005-05-03 | — | — | US | disclosed |
| US-20050085515-A1 | Carbamic acid compounds comprising a sulfonamide linkage as HDAC inhibitors | TOPO TARGET UK LIMITED, (GB) | 2005-04-21 | — | — | US | disclosed |
| US-20040077726-A1 | Carbamic acid compounds comprising a sulfonamide linkage as hdac inhibitors | SWK FUNDING LLC | 2004-04-22 | — | — | US | disclosed |
| EP-1328510-A2 | CARBAMIC ACID COMPOUNDS COMPRISING A SULFONAMIDE LINKAGE AS HDAC INHIBITORS | PROLIFIX LTD. (GB) | 2003-07-23 | — | — | EP | disclosed |
| WO-2002030879-A2 | CARBAMIC ACID COMPOUNDS COMPRISING A SULFONAMIDE LINKAGE AS HDAC INHIBITORS | PROLIFIX LIMITED (GB) | 2002-04-18 | — | — | WO | disclosed |
| EP-0570594-B1 | HYDROXAMIC ACID DERIVATIVE BASED ON AROMATIC SULFONAMIDE | SHIONOGI & CO (JP) | 1997-07-30 | — | — | EP | disclosed |
| US-5534654-A | ANTITUMOR, ANTIINFLAMMATORY, INHIBITOR OF LYMPHOCYTE ADHESIVE FACTORS | SHIONOGI & CO., LTD. (JP) | 1996-07-09 | — | — | US | disclosed |
| EP-0570594-A1 | HYDROXAMIC ACID DERIVATIVE BASED ON AROMATIC SULFONAMIDE | SHIONOGI & CO., LTD. (JP) | 1993-11-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180072661-A1 | PHARMACEUTICAL FORMULATIONS OF HDAC INHIBITORS | HDAC1, HDAC9, HDAC11 | HDAC8 11/4885HDAC1 1/4885HDAC3 8/4885 |
| US-20050107445-A1 | Carbamic acid compounds comprising a sulfonamide linkage as HDAC inhibitors | HDAC1, HDAC11, HDAC3 | HDAC8 4/4885HDAC1 1/4885HDAC3 3/4885 |
| US-20110105572-A1 | CARBAMIC ACID COMPOUNDS COMPRISING AN AMIDE LINKAGE AS HDAC INHIBITORS | HDAC1, HDAC7, HDAC5 | HDAC8 8/4885HDAC1 1/4885HDAC3 6/4885 |
| US-20040077726-A1 | Carbamic acid compounds comprising a sulfonamide linkage as hdac inhibitors | HDAC1, HDAC11, HDAC2 | HDAC8 4/4885HDAC1 1/4885HDAC3 5/4885 |
| US-20150031770-A1 | Pharmaceutical Formulations of HDAC Inhibitors | HDAC1, HDAC9, HDAC11 | HDAC8 11/4885HDAC1 1/4885HDAC3 8/4885 |
| US-20050085515-A1 | Carbamic acid compounds comprising a sulfonamide linkage as HDAC inhibitors | HDAC1, HDAC11, HDAC3 | HDAC8 4/4885HDAC1 1/4885HDAC3 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.